Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19011114 | MULTI-DOMAIN MOLECULES | January 2025 | March 2026 | Allow | 14 | 1 | 1 | Yes | No |
| 17995966 | HUMANIZED ANTIBODY TARGETING THE TUMOR ASSOCIATED ANTIGEN IL13RA2 | October 2022 | March 2026 | Allow | 41 | 1 | 0 | No | No |
| 17910608 | GLYPICAN-2-BINDING MOIETIES, CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | September 2022 | January 2026 | Allow | 40 | 1 | 1 | No | No |
| 17752650 | METHODS FOR TREATING POST INFECTIOUS AUTOIMMUNE DIABETES | May 2022 | March 2025 | Abandon | 34 | 2 | 0 | Yes | No |
| 17778519 | METHODS OF CANCER TREATMENT USING ANTI-OX40 ANTIBODIES IN COMBINATION WITH PI3 KINASE DELTA INHIBITORS | May 2022 | February 2026 | Abandon | 45 | 1 | 0 | No | No |
| 17746642 | CYTOLYTIC IMMUNE CELL COMPRISING BCMA- AND CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTORS | May 2022 | August 2025 | Allow | 39 | 1 | 0 | No | No |
| 17742947 | GENETICALLY ENGINEERED IMMUNE CELLS TARGETING CD70 FOR USE IN TREATING SOLID TUMORS | May 2022 | May 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17739444 | HSP Fusion Protein with Anti-Chemorepellant Agent for Treatment of Cancer | May 2022 | September 2025 | Allow | 41 | 2 | 1 | Yes | No |
| 17662042 | ANTI-TIGIT ANTIBODIES AND METHODS OF USE THEREOF | May 2022 | January 2026 | Allow | 45 | 3 | 1 | Yes | No |
| 17774214 | CD200 RECEPTOR ANTAGONIST BINDING MOLECULES | May 2022 | January 2026 | Abandon | 44 | 1 | 0 | No | No |
| 17721927 | METHODS AND COMPOSITIONS FOR TREATING DISEASE USING TARGETED FOXP3+CD4+ T CELLS AND CELLULAR SUICIDE AGENTS | April 2022 | April 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17762626 | TRIVALENT BINDING MOLECULES | March 2022 | February 2026 | Abandon | 46 | 1 | 0 | No | No |
| 17639103 | A SINGLE-DOMAIN ANTIBODY FOR TARGETING PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) | February 2022 | October 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17637778 | ANTIBODIES AND BLOCKING THE INTERACTION OF VISTA AND ITS BINDING PARTNER | February 2022 | August 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17652180 | CS1 ANTIBODY AND ANTI-CS1-CAR-T CELLS | February 2022 | June 2025 | Allow | 40 | 1 | 0 | No | No |
| 17637371 | HIGH-AFFINITY TCR FOR RECOGNIZING SSX2 ANTIGEN | February 2022 | February 2026 | Allow | 47 | 1 | 1 | Yes | No |
| 17637377 | NOVEL POLYPEPTIDE SELECTIVELY BINDING TO HUMAN PROGRAMMED CELL DEATH PROTEIN (PD-1) AND USE THEREOF | February 2022 | August 2025 | Allow | 42 | 1 | 0 | No | No |
| 17637433 | HINGE-MODIFIED IGG ANTIBODY COMPOSITIONS FOR PROTEASE RESISTANCE AND FC-GAMMA RECEPTOR BINDING AND METHODS OF MAKING THE SAME | February 2022 | February 2026 | Allow | 47 | 1 | 1 | Yes | No |
| 17635226 | CHIMERIC ANTIGEN RECEPTOR AND IMMUNE EFFECTOR CELL EXPRESSING CHIMERIC ANTIGEN RECEPTOR | February 2022 | August 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17635214 | METHOD FOR PRODUCING ENGINEERED TIRC7 SPECIFIC T-REGULATORY CELLS (TREGS) | February 2022 | December 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17633477 | ANTI-PD-1 and IL-15/IL-15Ra MULTIFUNCTIONAL ANTIBODY CONJUGATE, PREPARATION FOR SAME, AND USES THEREOF | February 2022 | November 2025 | Allow | 45 | 2 | 0 | No | No |
| 17633548 | USE OF IMMUNOCYTOKINE COMPRISING INTERFERON-BETA OR VARIANT THEREOF FOR TREATING HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE CANCER | February 2022 | December 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17584258 | METHODS AND COMPOSITIONS FOR ANTI-CD73 ANTIBODIES AND VARIANTS | January 2022 | December 2025 | Allow | 47 | 2 | 1 | Yes | No |
| 17626242 | CANINIZED ANTIBODIES TO HUMAN CTLA-4 | January 2022 | October 2025 | Allow | 45 | 2 | 0 | Yes | No |
| 17624795 | METHOD FOR TREATING TUMOR USING ANTI-CTLA4 SINGLE-DOMAIN ANTIBODIES | January 2022 | August 2025 | Allow | 43 | 2 | 0 | Yes | No |
| 17621931 | CD5 SPECIFIC T CELL RECEPTOR CELL OR GENE THERAPY | December 2021 | July 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17621182 | FUSION PROTEINS WITH ARGINASE ACTIVITY | December 2021 | August 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17644526 | NOVEL ICOS ANTIBODIES AND TUMOR-TARGETED ANTIGEN BINDING MOLECULES COMPRISING THEM | December 2021 | November 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17618061 | Methods for Removing Undesired Components During Multistage Chromatographic Processes | December 2021 | October 2025 | Allow | 46 | 2 | 0 | No | No |
| 17547178 | METHODS FOR TREATMENT OF CANCER COMPRISING TIGIT-BINDING AGENTS | December 2021 | October 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17616745 | pH-dependent Antigen-Binding Constructs Specific to FOLR 1 | December 2021 | December 2025 | Allow | 48 | 2 | 1 | Yes | No |
| 17616399 | ANTI-CEACAM5 MONOCLONAL ANTIBODY, PREPARATION METHOD THEREOF AND USE THEREOF | December 2021 | July 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17613823 | ANTI-TEM1 ANTIBODIES AND ANTIGEN-BINDING PORTIONS THEREOF | November 2021 | January 2025 | Allow | 38 | 0 | 1 | Yes | No |
| 17613698 | IMMUNOTHERAPY CONSTRUCTS TARGETING KRAS ANTIGENS | November 2021 | June 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17595637 | TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF | November 2021 | December 2025 | Allow | 49 | 1 | 1 | Yes | No |
| 17511230 | ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED ALPHA-SYNUCLEIN AGGREGATES | October 2021 | May 2025 | Allow | 43 | 1 | 1 | No | No |
| 17506993 | GENERATION OF ANTIBODY-DERIVED POLYPEPTIDES BY POLYPEPTIDE CHAIN EXCHANGE | October 2021 | March 2026 | Abandon | 52 | 1 | 1 | No | No |
| 17604209 | ANTAGONIST ANTI-CD7 ANTIBODIES | October 2021 | June 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17594269 | COMBINATIONS OF ANTI-ILDR2 ANTIBODIES AND PD-1 ANTAGONISTS | October 2021 | June 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17602593 | COMPOSITIONS AND METHODS FOR PROMOTING HEMATOPOIETIC CELL CYTOTOXICITY | October 2021 | October 2025 | Allow | 48 | 1 | 1 | Yes | No |
| 17602715 | ANTIBODY BINDING TO PD-1 | October 2021 | July 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17599492 | BINDING MOLECULES SPECIFIC FOR HBV ENVELOPE PROTEIN | September 2021 | January 2026 | Allow | 52 | 2 | 1 | Yes | No |
| 17593094 | HUMANIZED ANTI-FOLATE RECEPTOR 1 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | September 2021 | May 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17411638 | DOSING FOR TREATMENT WITH ANTI-TIGIT AND ANTI-CD20 OR ANTI-CD38 ANTIBODIES | August 2021 | October 2025 | Abandon | 49 | 0 | 1 | No | No |
| 17432563 | HDM2 ANTIBODY FOR USE IN TREATING CANCER | August 2021 | July 2025 | Abandon | 47 | 1 | 0 | No | No |
| 17432412 | COMBINATION THERAPY INVOLVING ANTI-CD39 ANTIBODIES AND ANTI-PD-1 OR ANTI-PD-L1 ANTIBODIES | August 2021 | September 2025 | Abandon | 49 | 1 | 1 | No | No |
| 17402320 | ANTIBODY MOLECULES THAT BIND TO NKP30 AND USES THEREOF | August 2021 | April 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17424541 | SPECIFIC T CELL RECEPTORS AGAINST EPITOPES OF MUTANT MYD88L265P PROTEIN FOR ADOPTIVE T CELL THERAPY | July 2021 | March 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17354610 | INTERFERON RECEPTOR 1 ANTIBODIES AND THEIR USES | June 2021 | June 2025 | Abandon | 48 | 1 | 0 | No | No |
| 17318996 | CHIMERIC ANTIGEN RECEPTOR SPACERS | May 2021 | January 2026 | Abandon | 56 | 3 | 2 | No | No |
| 17058999 | TUMOR-SPECIFIC NEOANTIGENS AND METHODS OF USING THE SAME | November 2020 | October 2025 | Allow | 58 | 4 | 1 | Yes | No |
| 13595460 | Protein C Zymogen and Methods of Use Thereof to Prevent Cancer Metastases | August 2012 | September 2025 | Allow | 60 | 15 | 1 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner CUNNINGCHEN, KATHLEEN MARY works in Art Unit 1646 and has examined 27 patent applications in our dataset. With an allowance rate of 51.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 47 months.
Examiner CUNNINGCHEN, KATHLEEN MARY's allowance rate of 51.9% places them in the 14% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by CUNNINGCHEN, KATHLEEN MARY receive 1.59 office actions before reaching final disposition. This places the examiner in the 30% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by CUNNINGCHEN, KATHLEEN MARY is 47 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +81.2% benefit to allowance rate for applications examined by CUNNINGCHEN, KATHLEEN MARY. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 16.7% of applications are subsequently allowed. This success rate is in the 13% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 50.0% of cases where such amendments are filed. This entry rate is in the 74% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.